ESC 365 - Insights from the vicadrostat phase 2 study and implications for further clinical development

Open Access

Insights from the vicadrostat phase 2 study and implications for further clinical development

Session: Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?

Topic: Aldosterone Antagonists

Speaker: Doctor R. Mentz (Durham, US)

Sponsored by Boehringer Ingelheim

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Robert Mentz

Duke University Medical Center, Durham (United States of America)

12 presentations

0 follower

6 more presentations in this session

Welcome and introductions

The integrated nature of cardiorenal metabolic health

Speaker: Professor L. Lund (Stockholm, SE)

The role of aldosterone and its part in cardiorenal disease

Speaker: Doctor M. Costanzo (Naperville, US)

Aldosterone synthase inhibition and the future CRM treatment landscape

Speaker: Professor J. Butler (Dallas, US)

Outlook, panel discussion and Q&A

Access the full session

Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?

Speakers: Doctor R. Mentz, Professor L. Lund, Doctor M. Costanzo, Professor J. Butler

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

Related content

Open Access

The integrated nature of cardiorenal metabolic health

19 May 2025

Open Access

Aldosterone synthase inhibition and the future CRM treatment landscape

19 May 2025

Open Access

Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?

19 May 2025

ESC 365 is supported by

novartis

Explore sponsored resources